局部晚期头颈部鳞状细胞癌每周与三周顺铂同步放化疗的比较分析
该系统性综述纳入1970至2015年间39项前瞻性研究共3668例患者,比较每周与三周顺铂同步放化疗的疗效与安全性。结果显示两组局部区域控制率、2年总生存和无进展生存均无显著差异,3-5级毒性亦无显著差异。结论认为每周顺铂方案在疗效与安全性上可媲美三周方案,支持两者均可用于局部晚期头颈部鳞状细胞癌,耐受性是选择的关键因素。
要点
- 每周与三周顺铂同步放化疗的局部区域控制率分别为58%和61%,无显著差异(P=.7)。
- 2年总生存每周组74% vs 三周组67%,2年无进展生存每周组69% vs 三周组62%,均无显著差异。
- 3-5级毒性每周组36% vs 三周组40%,无显著差异(P=.37),耐受性是方案选择关键因素。
核心结论
- 每周顺铂方案在疗效与安全性上可媲美三周方案,支持两者均可用于局部晚期头颈部鳞状细胞癌,耐受性是选择的关键因素。
研究设计与样本
- 系统性综述,从1970至2015年间1500项前瞻性研究中纳入39项(18项每周方案,21项三周方案),共3668例患者。
- 采用加权估计和双尾t检验进行比较,显著性水平为0.05。
主要发现
- 局部区域控制率每周组58%(CI 53%-63%)vs 三周组61%(CI 56%-65%),P=.7。
- 2年总生存每周组74%(CI 66%-80%)vs 三周组67%(CI 64%-69%),P=.67。
- 2年无进展生存每周组69%(CI 59%-77%)vs 三周组62%(CI 58%-65%),P=.9。
- 3-5级毒性每周组36% vs 三周组40%,P=.37。
关键数值与推荐
- 局部区域控制率:每周组58%(CI 53%-63%)vs 三周组61%(CI 56%-65%),P=.7。
- 2年总生存:每周组74%(CI 66%-80%)vs 三周组67%(CI 64%-69%),P=.67。
- 2年无进展生存:每周组69%(CI 59%-77%)vs 三周组62%(CI 58%-65%),P=.9。
- 3-5级毒性:每周组36% vs 三周组40%,P=.37。
临床怎么用
- 作者认为每周或三周顺铂方案均可用于局部晚期头颈部鳞状细胞癌,耐受性是选择方案的关键因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based chemoradiotherapy is standard of care for locally advanced squamous cell carcinoma of the head and neck. This systemic review compared efficacy and safety of weekly vs triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck. METHODS: Among 1500 prospective studies published from 1970 to 2015, 39 (18 weekly, 21 triweekly) including 3668 patients qualified for inclusion. Clinical outcomes were analyzed using weighted estimates and 2-tailed t test for comparisons; significance level was 0.05. RESULTS: Locoregional control was 58% (CI 53%-63%) vs 61% (CI 56%-65%; P = .7). The 2-year overall survival (OS) was 74% (CI 66%-80%) for weekly vs 67% (64%-69%) triweekly groups (P = .67). The 2-year progression-free survival (PFS) was 69% (CI 59%-77%) for weekly vs 62% (CI 58%-65%) triweekly groups (P = .9). Grade 3 to 5 toxicities were 36% vs 40% (P = .37) in weekly vs triweekly groups. CONCLUSIONS: Weekly cisplatin was comparable in efficacy and safety to the triweekly regimen. Our analysis supports the use of weekly or triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck, with tolerability being a key factor in selection.
引用
- Mohamed A, Twardy B, Zordok MA, et al. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis. Head Neck. 2019. PMID: 30835900. doi:10.1002/hed.25379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。